ELTX

AI Memo

Elicio Therapeutics

As of 2026-09-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q4 2026 ELI-002 7P combination-trial start • 2026-12-31

Base target: $2 / p=50% prob

Biggest risk

The central Phase 2 AMPLIFY-7P study missed its primary endpoint, leaving the registrational thesis dependent on subgroup interpretation, regulatory acceptance, future funding, and successful execution. The financing improves near-term liquidity but does not remove dilution or runway risk. [#PR-EARNINGS-2026-08-13]

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The Q2 update restores some optionality through a $15 million financing, stated runway into Q1 2027, a planned Q4 combination study, multiple reported complete responses, and activation of the MSK-led trial. Positive combination data or a credible R0-focused development path could produce asymmetric upside, but the clinical observations remain early and company-reported. [#PR-EARNINGS-2026-08-13]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-03

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and dilution checkpoint after July financing
MSK-led neoadjuvant Phase 1 execution
R0-selected Phase 3 and regulatory path

BearKey bullets

A delay or weak signal from the planned Q4 2026 combination study could pressure the stock materially.
AMPLIFY-7P missed its primary endpoint, weakening the original development thesis.
Cash runway is stated only into Q1 2027, creating potential financing and dilution risk.

WatchKey bullets

Q4 2026 ELI-002 7P combination-trial start

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +127% / -57%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $2 (p=50%)Bear Target: $1 (p=30%)

Commentary

News tone is mixed-to-negative: the financing and new trials add optionality, but the primary-endpoint miss remains the dominant fact. The packet does not provide verified post-print price reaction, analyst estimate revisions, options skew, short interest, employee sentiment, or social coverage; missing data are not treated as positive evidence. The appropriate stance is cautious monitoring rather than a confident rebound thesis.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and dilution checkpoint after July financing
MSK-led neoadjuvant Phase 1 execution
R0-selected Phase 3 and regulatory path

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 2026 ELI-002 7P combination-trial start
Elicio anticipates initiating a Phase 1 study of ELI-002 7P with a RAS small-molecule inhibitor, with or without anti-PD-1 therapy, in metastatic pancreatic cancer during Q4 2026. The event could restore optionality, but no efficacy data from the combination are yet available. [#PR-EARNINGS-2026-08-13]
Prob 65.00% • Move 25.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Runway and dilution checkpoint after July financing
2026-12-31
The $15 million July financing extends stated cash runway into Q1 2027, but the company remains dependent on additional financing or partnering to sustain development, leaving dilution and funding risk as the near-term trading overhang. [#PR-EARNINGS-2026-08-13]
Prob 75% • Move -18% • Priced-in 55%

Long-term Catalysts

Months to a year

MSK-led neoadjuvant Phase 1 execution
2027-03-31
An investigator-initiated, Memorial Sloan Kettering-led Phase 1 trial evaluating ELI-002 7P with chemotherapy and checkpoint inhibition has been activated. Progress toward treatment and early clinical observations could provide longer-horizon validation, subject to enrollment and execution risk. [#PR-EARNINGS-2026-08-13]
Prob 40% • Move 30% • Priced-in 20%
R0-selected Phase 3 and regulatory path
2027-06-30
AMPLIFY-7P missed its primary endpoint, and Elicio is evaluating prespecified subgroups including R0-resected patients to refine a potential Phase 3 strategy. Regulatory alignment and credible funding for that path remain unresolved. [#PR-EARNINGS-2026-08-13]
Prob 30% • Move 50% • Priced-in 15%

Risks

A delay or weak signal from the planned Q4 2026 combination study could pressure the stock materially.
AMPLIFY-7P missed its primary endpoint, weakening the original development thesis.
Cash runway is stated only into Q1 2027, creating potential financing and dilution risk.
Clinical programs remain early-stage, with enrollment, safety, efficacy, and timing uncertainty.
Low coverage and limited verified analyst-revision data reduce confidence in price targets.
R0 subgroup findings and future Phase 3 strategy require regulatory validation and may not reproduce prospectively.
The peer set lacks a direct asset or indication match, limiting relative-valuation confidence.

Peers

Symbol	Summary
CRBP	Useful small-cap biotech comparison for binary clinical-event trading and capital-markets dependence, although asset overlap and indication comparability are limited; not used as a direct valuation peer.
SPRO	Relevant development-stage biotech comparison where financing runway and discrete trial or regulatory catalysts can dominate equity value, but it is not a direct asset or indication match.
MCRB	Broader clinical-stage biotech comparator illustrating how single-program execution, regulatory visibility, and balance-sheet pressure can outweigh pipeline optionality; valuation comparability remains weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

CRBP

Useful small-cap biotech comparison for binary clinical-event trading and capital-markets dependence, although asset overlap and indication comparability are limited; not used as a direct valuation peer.

SPRO

Relevant development-stage biotech comparison where financing runway and discrete trial or regulatory catalysts can dominate equity value, but it is not a direct asset or indication match.

MCRB

Broader clinical-stage biotech comparator illustrating how single-program execution, regulatory visibility, and balance-sheet pressure can outweigh pipeline optionality; valuation comparability remains weak.